216 results on '"Shizuru J"'
Search Results
2. Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning
3. Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile
4. Chimerism, Graft Survival, and Withdrawal of Immunosuppressive Drugs in HLA Matched and Mismatched Patients After Living Donor Kidney and Hematopoietic Cell Transplantation
5. Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma
6. Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation
7. Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
8. Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure
9. Tolerance, Mixed Chimerism, and Graft Survival in HLA Matched and Mismatched Recipients of Kidney and Hematopoietic Cell Transplants.: Abstract# C2096
10. Complementing mutations in core binding factor leukemias: from mouse models to clinical applications
11. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML
12. B6.g7 mice reconstituted with BDC2·5 non-obese diabetic (BDC2·5NOD) stem cells do not develop autoimmune diabetes
13. Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants
14. Genetic control of diabetes mellitus
15. Developement of peripheral blood dendritic cell chimerism after allogeneic stem cell transplantation: 822
16. Non-myeloablative hematopoietic stem cell transplantation
17. Five-year Follow up of Patients with Advanced Chronic Lymphocytic Leukemia Treated with Allogeneic Hematopoietic Cell Transplantation Following Nonmyeloablative Conditioning
18. Longer follow up of patients (PTS) with advanced chronic lymphocytic leukemia (CLL) treated with nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT)
19. Hematopoietic Cell Transplants (HCT) from HLA-Matched Related (MRD) and Unrelated (URD) Donors for Patients with Hematologic Malignancies Using Low-Dose TBI Conditioning
20. Unrelated Donor Peripheral Blood Stem Cell (PBSC) Transplantation Using Nonmyeloablative Conditioning and Mycophenolate Mofetil (MMF) TID Results in High Engraftment Rates
21. Tolerance, Mixed Chimerism, and Graft Survival in HLA Matched and Mismatched Recipients of Kidney and Hematopoietic Cell Transplants.
22. European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
23. LOW DOSE TBI CONDITIONING FOR HEMATOPOIETIC STEM CELL TRANSPLANTS (HSCT) FROM HLA-MATCHED RELATED DONORS FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES: INFLUENCE OF FLUDARABINE OR CYTOREDUCTIVE AUTOGRAFTS ON OUTCOME
24. NONMYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTS (HSCT) FROM HLA-MATCHED RELATED DONORS FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES: CLINICAL RESULTS OF A TBI-BASED CONDITIONING REGIMEN
25. Allogeneic hematopoietic stem cell transplantation: from the nuclear age into the twenty-first century
26. From stem cells to lymphocytes:biology and transplantation
27. A DecadeʼS Experience with Safety and Efficacy of Tolerance Induction in Clinical Kidney Transplantation
28. Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma
29. Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation
30. INDUCING TOLERANCE IN CLINICAL KIDNEY TRANSPLANTATION
31. Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
32. Treatment Of Pediatric High-Risk Malignancies Using Non-Myeloablative (NM) Hematopoietic Cell Transplantation (HCT): A Multi-Institutional Experience
33. Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure
34. Long-term outcomes of high-dose therapy using busulfan, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for patients with high-risk or advanced stages of myeloid malignancies
35. Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Non-Myeloablative Conditioning with Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Confirm a Low Incidence of Graft Versus Host Disease (GVHD) with Retained Anti-Tumor Activity
36. INFLUENCE OF CHIMERISM ON TOLERANCE AFTER COMBINED HUMAN KIDNEY AND HEMATOPOIETIC CELL TRANSPLANTATION
37. Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).
38. 283: Rituximab infusion two months after total lymphoid irradiation-antithymocyte globulin (TLI-ATG) nonmyeloablative transplantation maintains B-cell disease control with minimal GVHD
39. 368: Longer follow up of patients (pts) with advanced chronic lymphocytic leukemia (CLL) treated with nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT)
40. In vivo selection of liver cells in a model of allogeneic bone-marrow-transplantation
41. Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning after Failed Myeloablative HCT: Factors Affecting Outcomes.
42. Haploidentical Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Conditioning Protects Against Acute Graft Versus Host Disease (GVHD).
43. A phase I trial with extended cohort of gemcitabine and vinorelbine followed by autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin’s lymphoma
44. Unrelated Donor Peripheral Blood Stem Cell (PBSC) Transplantation Using Nonmyeloablative Conditioning and Mycophenolate Mofetil (MMF) TID Results in High Engraftment Rates.
45. HLA-Matched Related (MRD) or Unrelated Donor (URD) Non-Myeloablative Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Refractory and Relapsed Aggressive Non Hodgkin Lymphoma (NHL).
46. Nonmyeloablative conditioning for stem cell allografts with low-dose tbi
47. Lymphoid Development from Stem Cells and the Common Lymphocyte Progenitors
48. Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction.
49. Vascular addressins are induced on islet vessels during insulitis in nonobese diabetic mice and are involved in lymphoid cell binding to islet endothelium.
50. Anti-CD8 abrogates effect of anti-CD4-mediated islet allograft survival in rat model
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.